N-Nitroso Fedratinib Impurity 1
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds. Fedratinib is used to treat adults with certain types of myelofibrosis (MF; a cancer of the bone marrow in which the bone marrow is replaced by scar tissue and causes decreased blood cell production). Fedratinib is in a class of medications called kinase inhibitors.N-Nitroso Fedratinib Impurity 1 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
N-Nitroso Fedratinib Impurity 1 CAS NO:NA Chemically represented as N-(Tert-butyl)-3-((5-methyl-2-(nitroso(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)pyrimidin-4-yl) (nitroso) amino) benzenesulfonamide .Synchemia is the leading manufacturing and exporter of N-Nitroso Fedratinib Impurity 1.We supply N-Nitroso Fedratinib Impurity 1 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0142291 |
| CAS No | NA |
| Mol.F. | C9H11N3O4 |
| Mol.Wt. | 225.2 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142292 |
| CAS No | NA |
| Mol.F. | C16H13ClN4O2 |
| Mol.Wt. | 328.76 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142293 |
| CAS No | NA |
| Mol.F. | C18H15ClN4O2 |
| Mol.Wt. | 354.79 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142294 |
| CAS No | NA |
| Mol.F. | C16H13ClN4O2 |
| Mol.Wt. | 328.76 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142295 |
| CAS No | NA |
| Mol.F. | C20H21ClN4O3 |
| Mol.Wt. | 400.86 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142296 |
| CAS No | NA |
| Mol.F. | C18H19ClN4O2 |
| Mol.Wt. | 358.83 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142297 |
| CAS No | NA |
| Mol.F. | C17H15ClN4O3 |
| Mol.Wt. | 358.78 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142298 |
| CAS No | NA |
| Mol.F. | C17H15ClN4O3 |
| Mol.Wt. | 358.78 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142299 |
| CAS No | NA |
| Mol.F. | C17H17ClN4O3 |
| Mol.Wt. | 360.8 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142300 |
| CAS No | NA |
| Mol.F. | C17H17ClN4O3 |
| Mol.Wt. | 360.8 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142301 |
| CAS No | NA |
| Mol.F. | C13H7ClN2O3 |
| Mol.Wt. | 274.66 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142302 |
| CAS No | NA |
| Mol.F. | C16H18N4O6S |
| Mol.Wt. | 394.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142303 |
| CAS No | NA |
| Mol.F. | C16H20N4O7S |
| Mol.Wt. | 412.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142304 |
| CAS No | NA |
| Mol.F. | C15H20N4O5S |
| Mol.Wt. | 368.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142305 |
| CAS No | NA |
| Mol.F. | C48H55N11O17S3 |
| Mol.Wt. | 1154.2 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142306 |
| CAS No | NA |
| Mol.F. | C32H38N8O13S2 |
| Mol.Wt. | 806.8 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |